Why Ozempic Fails 1 in 10 People

Ozempic and Wegovy are everywhere right now. Millions of prescriptions, billions in revenue, and a cultural conversation that won't quit. But a Stanford Medicine and ETH Zurich study published in Genome Medicine found that roughly 10% of people carry genetic variants that make these drugs less effective. The researchers call it "GLP-1 resistance." If that holds up, it could reshape how doctors prescribe these medications.

What the study found

About 10% of the population carries variants in a gene called PAM (peptidyl-glycine alpha-amidating monooxygenase). This enzyme processes GLP-1, the gut hormone that drugs like Ozempic are designed to mimic. People with these PAM variants actually produce more GLP-1 than average. But their bodies don't respond to it properly.

Key Takeaway: Around 10% of people may carry genetic variants that reduce how well Ozempic-class drugs work, according to research from Stanford Medicine and ETH Zurich.

Here's the weird part. The researchers expected these individuals to have lower GLP-1 levels. What they found was the opposite. "Despite people with the PAM variant having higher circulating levels of GLP-1, we saw no evidence of higher biological activity," said Anna Gloyn, professor of pediatrics and genetics at Stanford. More hormone, same (or worse) result.

A decade of verification

This wasn't a quick finding. The team spent ten years checking their own work through multiple approaches. They tested humans (with and without the PAM variant called p.S539W), ran parallel experiments in mice, and analyzed clinical trial data. In the trials, people with PAM variants couldn't lower blood glucose as effectively after six months of treatment.

Stat: People with PAM gene variants needed higher levels of GLP-1 to achieve the same blood sugar response as those without the variants.

The mice told the same story. When researchers gave mice with a PAM variant the GLP-1 drug liraglutide, their blood sugar dropped less than in normal mice given the same dose.

What "GLP-1 resistance" actually means

Think of it like insulin resistance, but for a different hormone. With insulin resistance, the body produces insulin but cells don't respond well. GLP-1 resistance is the same idea: the hormone is there in higher amounts, but the biological signal gets muted somewhere along the way.

The frustrating part? Researchers still don't know exactly why. "We have ticked off this enormous list of all the ways in which we thought GLP-1 resistance might come about," Gloyn said. "No matter what we've done, we've not been able to nail precisely why they are resistant."

Key Takeaway: GLP-1 resistance works similarly to insulin resistance. The hormone is present in higher-than-normal amounts, but the body's response to it is blunted.

What this means for your plate

If you're among the roughly 10% who doesn't respond well to GLP-1 drugs, tracking what you eat matters more, not less. These medications work partly by suppressing appetite. When that mechanism is weaker, you can't lean on the drug alone to cut food intake.

Understanding your protein intake, meal timing, and overall calorie balance gives you actual data to work with. A food tracker that breaks down macronutrients (protein, carbs, fat, fiber) can reveal patterns that gut feeling alone won't catch.

Key Takeaway: For people who respond poorly to GLP-1 drugs, careful nutrition tracking may be especially important since the appetite-suppressing effect is weaker.

And honestly, the bigger lesson here goes beyond GLP-1. Your genetic makeup influences how you respond to food, supplements, and medications. The same drug that changes one person's life may barely register for someone else.

What comes next

The researchers hope genetic testing could eventually help doctors predict who will respond to GLP-1 drugs before prescribing them. "Knowing ahead of time who is likely to respond would help patients get on the right drugs faster, a step toward precision medicine," Gloyn said.

If you're on a GLP-1 medication and not seeing the results you expected, genetics could be part of the picture. Talk to your doctor. And pay closer attention to what you're eating. The data from your plate might matter more than you think.

FAQ

Does Ozempic work for everyone?

No. A Stanford and ETH Zurich study published in Genome Medicine found that about 10% of people carry PAM gene variants linked to "GLP-1 resistance," which may reduce how effectively drugs like Ozempic and Wegovy lower blood sugar. Research into weight-loss effects specifically is still ongoing.

What is GLP-1 resistance?

GLP-1 resistance is a newly identified phenomenon where the body produces higher-than-normal levels of the GLP-1 hormone but doesn't respond to it effectively. It was discovered in people carrying specific PAM gene variants. The concept parallels insulin resistance.

Can you test for GLP-1 resistance?

Not yet through routine clinical testing. The PAM gene variants (including p.S539W) were identified in research settings. The study authors hope genetic screening for GLP-1 drug response will eventually become part of standard care, but that step is still in the future.

Should I track my food while on Ozempic?

Tracking nutrition while on GLP-1 medications is widely recommended by healthcare professionals. These drugs suppress appetite, which can lead to eating less overall but missing key nutrients like protein. Monitoring macronutrients helps maintain muscle mass and nutritional balance during weight loss.

What should I do if Ozempic isn't working for me?

Talk to your doctor first. Several factors influence drug response: dosage, timing, diet, and now genetic variants. Your doctor may adjust your dose, switch medications, or recommend additional strategies like structured nutrition tracking.

-- Selena